Trade Report: Today, Obermeyer Wood Investment Counsel Lllp Buys 1,969 Shares of Shire PLC (SHPG)

Today, Obermeyer Wood Investment Counsel Lllp Buys 1,969  Shares of Shire PLC (SHPG)

Obermeyer Wood Investment Counsel Lllp acquired a new stake in shares of Shire PLC (NASDAQ:SHPG) during the third quarter, Holdings Channel reports. The institutional investor acquired 1,969 shares of the biopharmaceutical company’s stock, valued at approximately $382,000.

A number of other institutional investors also recently added to or reduced their stakes in SHPG. Rail Splitter Capital Management LLC bought a new position in Shire PLC during the second quarter valued at about $6,461,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $17,387,000. Bienville Capital Management LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $450,000. CAM Group Holding A S increased its stake in shares of Shire PLC by 1.5% in the second quarter. CAM Group Holding A S now owns 106,494 shares of the biopharmaceutical company’s stock valued at $19,603,000 after buying an additional 1,570 shares during the period. Finally, Westport Resources Management Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $318,000. Institutional investors own 24.49% of the company’s stock.

Shire PLC (NASDAQ:SHPG) opened at 173.88 on Friday. The firm has a market cap of $51.79 billion, a price-to-earnings ratio of 36.13 and a beta of 1.46. Shire PLC has a one year low of $147.60 and a one year high of $215.05. The firm has a 50 day moving average of $181.33 and a 200-day moving average of $187.46.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share for the quarter, missing analysts’ consensus estimates of $3.21 by $0.04. The company earned $3.45 billion during the quarter, compared to analyst estimates of $3.57 billion. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The company’s revenue was up 108.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.24 earnings per share. Equities research analysts forecast that Shire PLC will post $12.93 EPS for the current fiscal year.

SHPG has been the subject of several recent research reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research note on Monday, August 1st. Guggenheim reiterated a “neutral” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Leerink Swann reiterated an “outperform” rating and set a $231.00 target price (up previously from $213.00) on shares of Shire PLC in a research note on Wednesday, August 3rd. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Finally, RBC Capital Markets reiterated an “outperform” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $222.06.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Related posts

Leave a Comment